Scarica l'app Stockscreener
7.00
3.45%
-0.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Precedente Chiudi:
$7.25
Aprire:
$7.35
Volume 24 ore:
640.36K
Relative Volume:
0.72
Capitalizzazione di mercato:
$1.10B
Reddito:
$61.10M
Utile/perdita netta:
$-138.36M
Rapporto P/E:
-5.1852
EPS:
-1.35
Flusso di cassa netto:
$-90.59M
1 W Prestazione:
-3.85%
1M Prestazione:
-13.47%
6M Prestazione:
-24.16%
1 anno Prestazione:
-6.91%
Intervallo 1D:
$6.99
$7.41
Intervallo di 1 settimana:
$6.99
$7.515
Portata 52W:
$4.06
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Nome
Ocular Therapeutix Inc
Settore
Industria
Telefono
781-357-4000
Indirizzo
15 CROSBY DRIVE, BEDFORD, MA
Confronta OCUL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
7.00 | 1.10B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-20 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-02-09 | Iniziato | BofA Securities | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-10 | Ripresa | Berenberg | Buy |
| 2021-08-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-11-13 | Reiterato | Raymond James | Strong Buy |
| 2020-08-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-05-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Iniziato | Raymond James | Strong Buy |
| 2018-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-07-12 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-08-11 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Legato Capital Management LLC Sells 34,695 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix CEO gets new compensation package - MSN
Ocular Therapeutix Approves New CEO Compensation Package - TipRanks
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $17.00 Consensus Price Target from Brokerages - Defense World
Ocular Hypertension Clinical and Non-Clinical Studies, Key - openPR
How to Take Advantage of moves in (OCUL) - Stock Traders Daily
DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Donald Notman Sells 6,301 Shares - MarketBeat
The OCUL Stock Puzzle: Unraveling Ocular Therapeutix Inc’s Fluctuating Performance - The InvestChronicle
Analytical Overview: Ocular Therapeutix Inc (OCUL)’s Ratios Tell a Financial Story - The Dwinnex
Is Ocular Therapeutix Inc (OCUL) a good investment opportunity? - US Post News
Raymond James maintains $19 target on Ocular Therapeutix stock - MSN
Ocular Therapeutix Inc (OCUL) may enjoy gains as insiders got busy in the recent days - Knox Daily
Raymond James maintains $19 target on Ocular Therapeutix stock By Investing.com - Investing.com Canada
Ocular Therapeutix CFO Donald Notman sells $136,238 in stock By Investing.com - Investing.com Canada
Ocular Therapeutix CFO Donald Notman sells $136,238 in stock - Investing.com India
There is no way Ocular Therapeutix Inc (OCUL) can keep these numbers up - SETE News
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) institutional investors lost 4.3% last week but have benefitted from longer-term gains - Simply Wall St
Ocular Therapeutix™ Announces Upcoming Presentations at the - GlobeNewswire
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting - The Manila Times
Ocular Therapeutix, Inc. Announces Presentations at Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting - Nasdaq
Revolutionary Eye Treatment Data: Ocular's OTX-TKI Takes Center Stage at Premier Medical Conference - StockTitan
Ocular Therapeutix (NASDAQ:OCUL) Shares Cross Below 200 Day Moving AverageHere's What Happened - MarketBeat
SG Americas Securities LLC Buys 26,511 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix (NASDAQ:OCUL) Share Price Passes Below 200-Day Moving Average – Should You Sell? - Defense World
Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire
RoundAngle Advisors LLC Invests $1.70 Million in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) and Verona Pharma (NASDAQ:VRNA) Financial Contrast - Defense World
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ocular Therapeutix Grants Stock Options and RSU Awards to New Employee in Incentive Plan - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Ocular Therapeutix (STU:0OT) Cash From Discontinued Investi - GuruFocus.com
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR - GlobeNewswire
Ocular Therapeutix progresses with AXPAXLI trials for eye diseases By Investing.com - Investing.com Canada
Ocular Therapeutix progresses with AXPAXLI trials for eye diseases - Investing.com India
Ocular Therapeutix Advances AXPAXLI Eye Treatment Trials with Strong Enrollment Milestone - StockTitan
Neuropathic Ocular Pain Market Is Booming Worldwide 2025-2032 | - openPR
Investors push Ocular Therapeutix (NASDAQ:OCUL) 6.3% lower this week, company's increasing losses might be to blame - Simply Wall St
Learn to Evaluate (OCUL) using the Charts - Stock Traders Daily
OCULOcular Therapeutix, Inc. Latest Stock News & Market Updates - StockTitan
Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation - The Manila Times
Ocular Therapeutix™ to Provide Corporate Update During 43rd - GlobeNewswire
Ocular Therapeutix CEO to Present AXPAXLI Trial Updates at J.P. Morgan Healthcare Conference - StockTitan
Ocular Therapeutix Inc Azioni (OCUL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ocular Therapeutix Inc Azioni (OCUL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Notman Donald | See Remarks |
Jan 31 '25 |
Sale |
7.84 |
6,301 |
49,400 |
204,563 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):